Market Closed -
Nasdaq
21:00:00 21/06/2024 BST
|
5-day change
|
1st Jan Change
|
3.16
USD
|
-2.77%
|
|
-8.93%
|
-61.18%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
99.63
|
361.6
|
373.5
|
84.56
|
205.7
|
80.03
|
-
|
-
|
Enterprise Value (EV)
1 |
99.63
|
361.6
|
373.5
|
84.56
|
205.7
|
80.03
|
80.03
|
80.03
|
P/E ratio
|
-0.67
x
|
-4.84
x
|
-5
x
|
-1.06
x
|
-2.06
x
|
-0.79
x
|
-0.98
x
|
-1.38
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.71
x
|
4.09
x
|
182
x
|
32.6
x
|
-
|
400
x
|
4.99
x
|
1.23
x
|
EV / Revenue
|
5.71
x
|
4.09
x
|
182
x
|
32.6
x
|
-
|
400
x
|
4.99
x
|
1.23
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-0.86
x
|
-
|
-
|
-
|
-
|
-0.68
x
|
-0.74
x
|
-0.71
x
|
FCF Yield
|
-116%
|
-
|
-
|
-
|
-
|
-146%
|
-135%
|
-141%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,196
|
14,148
|
15,182
|
17,508
|
25,268
|
25,326
|
-
|
-
|
Reference price
2 |
16.08
|
25.56
|
24.60
|
4.830
|
8.140
|
3.160
|
3.160
|
3.160
|
Announcement Date
|
11/03/20
|
18/03/21
|
28/03/22
|
14/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
17.46
|
88.52
|
2.053
|
2.596
|
-
|
0.2
|
16.05
|
65.19
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-132.3
|
-49.36
|
-61.41
|
-72.94
|
-92.08
|
-117.1
|
-123.4
|
-107
|
Operating Margin
|
-758.14%
|
-55.76%
|
-2,991.18%
|
-2,809.59%
|
-
|
-58,529.31%
|
-768.65%
|
-164.15%
|
Earnings before Tax (EBT)
1 |
-149.2
|
-67.53
|
-71.2
|
-73.81
|
-87.37
|
-119.8
|
-119.1
|
-95.4
|
Net income
1 |
-149.2
|
-67.73
|
-71.2
|
-73.81
|
-87.37
|
-119.4
|
-119.1
|
-95.4
|
Net margin
|
-854.77%
|
-76.51%
|
-3,468.1%
|
-2,843.3%
|
-
|
-59,717.07%
|
-741.76%
|
-146.34%
|
EPS
2 |
-24.00
|
-5.280
|
-4.920
|
-4.560
|
-3.960
|
-4.000
|
-3.213
|
-2.290
|
Free Cash Flow
1 |
-115.6
|
-
|
-
|
-
|
-
|
-117
|
-108
|
-112.5
|
FCF margin
|
-662.13%
|
-
|
-
|
-
|
-
|
-58,500%
|
-672.75%
|
-172.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
18/03/21
|
28/03/22
|
14/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.545
|
2.596
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.05
|
0.05
|
0.1
|
0.2667
|
0.8667
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.51
|
-16.98
|
-21.4
|
-17.71
|
-16.85
|
-19.34
|
-20.29
|
-21.31
|
-31.14
|
-28.06
|
-28.72
|
-29.74
|
-30.55
|
-30
|
-29
|
Operating Margin
|
-3,029.54%
|
-654.08%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-57,446.76%
|
-59,472.24%
|
-30,554.75%
|
-11,249.86%
|
-3,346.14%
|
Earnings before Tax (EBT)
1 |
-16.48
|
-16.96
|
-21.95
|
-18.09
|
-16.81
|
-15.71
|
-24.28
|
-20
|
-27.37
|
-33.86
|
-28.44
|
-29.49
|
-30.4
|
-31
|
-31
|
Net income
1 |
-16.48
|
-16.96
|
-21.95
|
-18.09
|
-16.81
|
-15.71
|
-24.28
|
-20
|
-27.37
|
-33.86
|
-28.44
|
-29.49
|
-30.4
|
-31
|
-31
|
Net margin
|
-3,024.04%
|
-653.39%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-56,884.66%
|
-58,982%
|
-30,403.33%
|
-11,624.85%
|
-3,576.91%
|
EPS
2 |
-1.200
|
-1.080
|
-1.440
|
-1.080
|
-0.9600
|
-0.9600
|
-1.370
|
-0.7500
|
-1.020
|
-1.260
|
-1.007
|
-0.9843
|
-0.8943
|
-0.9200
|
-0.9067
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/03/22
|
09/05/22
|
08/08/22
|
03/11/22
|
14/03/23
|
09/05/23
|
08/08/23
|
08/11/23
|
14/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-116
|
-
|
-
|
-
|
-
|
-117
|
-108
|
-113
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.01
|
0.03
|
0.2
|
-
|
-
|
0.25
|
0.13
|
0.13
|
Capex / Sales
|
0.04%
|
0.04%
|
9.55%
|
-
|
-
|
125%
|
0.78%
|
0.19%
|
Announcement Date
|
11/03/20
|
18/03/21
|
28/03/22
|
14/03/23
|
14/03/24
|
-
|
-
|
-
|
Last Close Price
3.16
USD Average target price
22.5
USD Spread / Average Target +612.03% Consensus |
1st Jan change
|
Capi.
|
---|
| -61.18% | 80.03M | | +15.19% | 121B | | +19.91% | 114B | | +18.37% | 23.61B | | -19.80% | 20.43B | | -15.66% | 16.55B | | -13.45% | 16.45B | | -44.35% | 15.59B | | +66.67% | 15.19B | | +2.13% | 13.54B |
Bio Therapeutic Drugs
|